EGFR
Epidermal growth factor receptor
As of the edition of 20 October 2026, EGFR (epidermal growth factor receptor, UniProt P00533) has 109 drugs tested at it and 105 companies on the list, 30 on route A and 15 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P00533
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 393
- Disease areas
- Cancer; Lungs and airways; Digestive system; Skin and connective tissue; Hormones; Urinary and reproductive; Nervous system; Pregnancy and women's health
- Registered trials of its drugs
- 3,971
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 20 |
| Active | 32 |
| Went quiet | 19 |
| Stopped | 28 |
| Status not established | 10 |
| Total | 109 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Cetuximab | Marketed | Phase 4 | Ended 2016 |
| Erlotinib | Marketed | Phase 4 | none listed |
| Gefitinib | Marketed | Phase 4 | none listed |
| Osimertinib | Marketed | Phase 4 | Ends 2032 |
| Lapatinib | Marketed | Phase 4 | Ends 2029 |
| Panitumumab | Marketed | Phase 4 | Ended 2018 |
| Afatinib | Marketed | Phase 4 | Ends 2029 |
| Pyrotinib | Active | Phase 4 | none listed |
| Nimotuzumab | Stopped | Phase 4 | none listed |
| Vandetanib | Marketed | Phase 3 | none listed |
| Neratinib | Marketed | Phase 3 | Ends 2030 |
| Icotinib | Marketed | Phase 4 | none listed |
12 of 109 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 30 |
| Route B | 15 |
| Engaged | 49 |
| Undetermined | 11 |
| Total on the list | 105 |
The other 102 companies at EGFR
In the product105 companies in all; 102 are not named here, and no score is.
See the 105 companies at EGFR, ranked, with the facts behind eachRequest access. Nothing is shown until you do.